CME Courses 1-4
9 a.m.-4 p.m.
CME Courses 5-8
10 a.m.-5 p.m.
Registration/Course Enrollment Open
APA Resource Center Open
11 a.m.-5 p.m.
Publishers’ Bookfair Open
12:30 p.m.-3:30 p.m.
IS1. Schizophrenia Treatment in the Community: The Role of Long-Acting AntipsychoticsSupported by Janssen Pharmaceutica
A. Key Issues in Long-Term Pharmacotherapy of Schizophrenia William T. Carpenter Jr., M.D.
B. The Latest Advance in Long-Acting Antipsychotic Therapy John M. Kane, M.D.
C. Translating From Clinical Trials to Community Care for Patients With Schizophrenia Jacqueline M. Feldman, M.D.
D. Overcoming Obstacles to Patient Acceptance of Long-Acting Antipsychotics David C. Henderson, M.D.
IS2. Bipolar Disorder: Strategies for Stabilizing Patients Over the Long Term Supported by GlaxoSmithKline
A. New Results From the Stanley Bipolar Treatment Network Robert M. Post, M.D.
B. Update on Anticonvulsants for Bipolar Disorders Charles L. Bowden, M.D.
C. Practical Strategies to Avoid Medication-Induced Mood Destabilization in Bipolar Patients Carlos M. Zarate Jr., M.D.
D. Psychosocial Strategies to Promote Stabilization and Enhance Coping in Patients with Bipolar Disorder David J. Miklowitz, M.D.
IS3. Anxiety Disorders: Sources, Signs, and SolutionsSupported by Forest Laboratories Inc.
A. Examining Anxiety’s Underpinnings Christine Heim, Ph.D.
B. Anxious Body, Anxious Self, Anxious Psychiatrists Mack Lipkin, M.D.
C. Facing Up to Social Anxiety Disorder Murray B. Stein, M.D.
D. Generalized Anxiety Disorder: Beneath the Surface Jonathan R.T. Davidson, M.D.
E. The Neurobiology of Panic Disorder and OCD Stephen M. Stahl, M.D.
1 p.m.-5 p.m.
CME Courses 9-12
6 p.m.-9 p.m.
IS4. New Strategies for Managing Bipolar Disorder Supported by Janssen Pharmaceutica
A. Clinical Management of Bipolar Patients: A Difficult Task Dwight L. Evans, M.D.
B. Rational Polypharmacy in the Treatment of Patients With Bipolar Disorder S. Nassir Ghaemi, M.D.
C. Emerging Treatment for Bipolar Disorder: A New Role for Atypical Antipsychotics Lakshmi N. Yatham, M.D.
D. Complexities in the Treatment of Juvenile Bipolar Disorder Robert L. Findling, M.D.
IS5. Genetics and Psychiatry: Real Genes, Real ProgressSupported by AstraZeneca Pharmaceuticals
A. Genetic Engineering in Animals: New Insights About Anxiety and Antidepressants Rene Hen, Ph.D.
B. Recent Advances in Statistical and Gene-Finding Methods in Psychiatric Genetics Richard Straub, M.D.
C. Gene and Protein Expression in Brain: It Depends on Inheritance Joel E. Kleinman, M.D.
D. Rethinking the Concept of Phenotype in Psychiatry Robert Freedman, M.D.
E. In vivo Approaches to Identifying Genetic Mechanisms of Susceptibility Daniel R. Weinberger, M.D.
IS6. Beyond Benzodiazepines: New Molecules for the Treatment of Anxiety Supported by Pfizer Inc.
A. Childhood Anxiety Disorders: Does Treatment Affect Long-Term Outcome? Moira A. Rynn, M.D.
B. The Burden of Anxiety Disorders David V. Sheehan, M.D.
C. Treatment for Generalized Anxiety Disorder: Current and Near Term Stuart A. Montgomery, M.D.
D. Future Directions: New Molecular Targets for the Treatment of Anxiety Jack M. Gorman, M.D.
IS7. Enhancing Outcomes by Addressing Critical Challenges in the Treatment of SchizophreniaSupported by Eli Lilly and Company
A. Schizophrenia: New Understandings of the Early Stage of Illness Diana O. Perkins, M.D.
B. Improving Cognition for Quality Outcomes Richard S. Keefe, Ph.D.
C. Treatment Challenges for the Patient With Acute Agitation Leslie L. Citrome, M.D.
D. Metabolic Issues With Antipsychotic Therapy John B. Buse, M.D.
E. Maintenance Strategies: Balancing Efficacy and Safety to Prevent Relapse Thomas F. Liffick, M.D.
IS8. Optimizing Efficacy and Tolerability of Antidepressant Therapy: Does Selectivity of Action Matter?Supported by Forest Laboratories Inc.
A. The Alphabet Soup of Antidepressant Pharmacology: From TCAs and MAOIs to SSRIs, SNRIs, and Beyond Pedro L. Delgado, M.D.
B. SSRIs and Beyond: Spectrum of Efficacy of Newer Antidepressants Justine M. Kent, M.D.
C. Efficacy of Newer Antidepressants Michael E. Thase, M.D.
D. Generally Well Tolerated: Comparative Adverse-Event Profiles of Newer Antidepressants Andrew A. Nierenberg, M.D. ▪
Download citation file:
Please confirm that your email address is correct, so you can successfully receive this alert.
Read this week's Update
Sign Up for Psychiatric News Update newsletter